<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35411701</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1755-5949</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>28</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>CNS neuroscience &amp; therapeutics</Title>
          <ISOAbbreviation>CNS Neurosci Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Is COVID-19 severity associated with reduction in T lymphocytes in anti-CD20-treated people with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?</ArticleTitle>
        <Pagination>
          <StartPage>971</StartPage>
          <EndPage>973</EndPage>
          <MedlinePgn>971-973</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/cns.13841</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hoepner</LastName>
            <ForeName>Robert</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0002-0115-7021</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kamm</LastName>
            <ForeName>Christian P</ForeName>
            <Initials>CP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Neurocentre, Cantonal Hospital Lucerne, Lucerne, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Friedli</LastName>
            <ForeName>Christoph</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0001-7974-5432</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Salmen</LastName>
            <ForeName>Anke</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-4751-299X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chan</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>CNS Neurosci Ther</MedlineTA>
        <NlmUniqueID>101473265</NlmUniqueID>
        <ISSNLinking>1755-5930</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009471" MajorTopicYN="Y">Neuromyelitis Optica</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Dr Hoepner received speaker/advisor honorary from Merck, Novartis, Roche, Biogen, Alexion, Sanofi, Janssen, Bristol‐Myers Squibb, and Almirall. He received research support within the last 5 years from Roche, Merck, Sanofi, Biogen, Chiesi, and Bristol‐Myers Squibb. He also received research grants from the Swiss MS Society. He also serves as associated editor for Journal of Central Nervous System disease. All are not related to that work. Dr Kamm has received honoraria for lectures and research support from Biogen, Novartis, Almirall, Teva, Merck, Sanofi Genzyme, Roche, Eli Lilly, Janssen, Celgene, and the Swiss MS Society (SMSG). Friedli C received speaker honoraria and/or travel compensation for activities with Biogen, Sanofi Genzyme, Novartis, and Merck and research support from Chiesi, not related to this work. Dr Salmen received speaker honoraria and/or travel compensation for activities with Bristol‐Myers Squibb, Novartis, Roche, and research support by Baasch Medicus Foundation and the Swiss MS Society. She serves on the Editorial Board of Frontiers in Neurology—Multiple Sclerosis and Neuroimmunology. All are not related to this work. Dr Chan has received speakers’/board honoraria from Actelion (Janssen/J&amp;J), Almirall, Bayer, Biogen, Celgene (BMS), Genzyme, Merck KGaA (Darmstadt, Germany), Novartis, Roche, and Teva, all for hospital research funds. He received research support from Biogen, Genzyme, and UCB, the European Union, and the Swiss National Foundation. He serves as associate editor of the European Journal of Neurology, on the editorial board for Clinical and Translational Neuroscience and as topic editor for the Journal of International Medical Research.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>5</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35411701</ArticleId>
        <ArticleId IdType="pmc">PMC9062573</ArticleId>
        <ArticleId IdType="doi">10.1111/cns.13841</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Pistor M, Hoepner AGF, Lin Y, et al. Immunotherapies and COVID‐19 mortality: a multidisciplinary open data analysis based on FDA's Adverse Event Reporting System. Ann Rheum Dis. 2021;80(12):1633‐1635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8600608</ArticleId>
            <ArticleId IdType="pubmed">34285050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Poland GA, Ovsyannikova IG, Kennedy RB. SARS‐CoV‐2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020;396(10262):1595‐1606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7553736</ArticleId>
            <ArticleId IdType="pubmed">33065034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Furlan A, Forner G, Cipriani L, et al. COVID‐19 in B cell‐depleted patients after rituximab: a diagnostic and therapeutic challenge. Front Immunol. 2021;12:763412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8595333</ArticleId>
            <ArticleId IdType="pubmed">34804051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gingele S, Skripuletz T, Jacobs R. Role of CD20(+) T cells in multiple sclerosis: implications for treatment with ocrelizumab. Neural Regen Res. 2020;15(4):663‐664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6975146</ArticleId>
            <ArticleId IdType="pubmed">31638088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hughes R, Whitley L, Fitovski K, et al. COVID‐19 in ocrelizumab‐treated people with multiple sclerosis. Mult Scler Relat Disord. 2021;49:102725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7772086</ArticleId>
            <ArticleId IdType="pubmed">33482590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Anonymos
. 2022. Available from: https://www.worldometers.info/coronavirus/
</Citation>
        </Reference>
        <Reference>
          <Citation>
Salter A, Fox RJ, Newsome SD, et al. Outcomes and Risk Factors Associated With SARS‐CoV‐2 Infection in a North American Registry of Patients With Multiple Sclerosis. JAMA Neurol. 2021;78(6):699‐708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7980147</ArticleId>
            <ArticleId IdType="pubmed">33739362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sormani MP, Salvetti M, Labauge P, et al. DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France. Ann Clin Transl Neurol. 2021;8(8):1738‐1744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8351392</ArticleId>
            <ArticleId IdType="pubmed">34240579</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35411701</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1755-5949</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>28</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>CNS neuroscience &amp; therapeutics</Title>
          <ISOAbbreviation>CNS Neurosci Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Is COVID-19 severity associated with reduction in T lymphocytes in anti-CD20-treated people with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?</ArticleTitle>
        <Pagination>
          <StartPage>971</StartPage>
          <EndPage>973</EndPage>
          <MedlinePgn>971-973</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/cns.13841</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hoepner</LastName>
            <ForeName>Robert</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0002-0115-7021</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kamm</LastName>
            <ForeName>Christian P</ForeName>
            <Initials>CP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Neurocentre, Cantonal Hospital Lucerne, Lucerne, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Friedli</LastName>
            <ForeName>Christoph</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0001-7974-5432</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Salmen</LastName>
            <ForeName>Anke</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-4751-299X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chan</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>CNS Neurosci Ther</MedlineTA>
        <NlmUniqueID>101473265</NlmUniqueID>
        <ISSNLinking>1755-5930</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009471" MajorTopicYN="Y">Neuromyelitis Optica</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Dr Hoepner received speaker/advisor honorary from Merck, Novartis, Roche, Biogen, Alexion, Sanofi, Janssen, Bristol‐Myers Squibb, and Almirall. He received research support within the last 5 years from Roche, Merck, Sanofi, Biogen, Chiesi, and Bristol‐Myers Squibb. He also received research grants from the Swiss MS Society. He also serves as associated editor for Journal of Central Nervous System disease. All are not related to that work. Dr Kamm has received honoraria for lectures and research support from Biogen, Novartis, Almirall, Teva, Merck, Sanofi Genzyme, Roche, Eli Lilly, Janssen, Celgene, and the Swiss MS Society (SMSG). Friedli C received speaker honoraria and/or travel compensation for activities with Biogen, Sanofi Genzyme, Novartis, and Merck and research support from Chiesi, not related to this work. Dr Salmen received speaker honoraria and/or travel compensation for activities with Bristol‐Myers Squibb, Novartis, Roche, and research support by Baasch Medicus Foundation and the Swiss MS Society. She serves on the Editorial Board of Frontiers in Neurology—Multiple Sclerosis and Neuroimmunology. All are not related to this work. Dr Chan has received speakers’/board honoraria from Actelion (Janssen/J&amp;J), Almirall, Bayer, Biogen, Celgene (BMS), Genzyme, Merck KGaA (Darmstadt, Germany), Novartis, Roche, and Teva, all for hospital research funds. He received research support from Biogen, Genzyme, and UCB, the European Union, and the Swiss National Foundation. He serves as associate editor of the European Journal of Neurology, on the editorial board for Clinical and Translational Neuroscience and as topic editor for the Journal of International Medical Research.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>5</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35411701</ArticleId>
        <ArticleId IdType="pmc">PMC9062573</ArticleId>
        <ArticleId IdType="doi">10.1111/cns.13841</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Pistor M, Hoepner AGF, Lin Y, et al. Immunotherapies and COVID‐19 mortality: a multidisciplinary open data analysis based on FDA's Adverse Event Reporting System. Ann Rheum Dis. 2021;80(12):1633‐1635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8600608</ArticleId>
            <ArticleId IdType="pubmed">34285050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Poland GA, Ovsyannikova IG, Kennedy RB. SARS‐CoV‐2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020;396(10262):1595‐1606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7553736</ArticleId>
            <ArticleId IdType="pubmed">33065034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Furlan A, Forner G, Cipriani L, et al. COVID‐19 in B cell‐depleted patients after rituximab: a diagnostic and therapeutic challenge. Front Immunol. 2021;12:763412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8595333</ArticleId>
            <ArticleId IdType="pubmed">34804051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gingele S, Skripuletz T, Jacobs R. Role of CD20(+) T cells in multiple sclerosis: implications for treatment with ocrelizumab. Neural Regen Res. 2020;15(4):663‐664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6975146</ArticleId>
            <ArticleId IdType="pubmed">31638088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hughes R, Whitley L, Fitovski K, et al. COVID‐19 in ocrelizumab‐treated people with multiple sclerosis. Mult Scler Relat Disord. 2021;49:102725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7772086</ArticleId>
            <ArticleId IdType="pubmed">33482590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Anonymos
. 2022. Available from: https://www.worldometers.info/coronavirus/
</Citation>
        </Reference>
        <Reference>
          <Citation>
Salter A, Fox RJ, Newsome SD, et al. Outcomes and Risk Factors Associated With SARS‐CoV‐2 Infection in a North American Registry of Patients With Multiple Sclerosis. JAMA Neurol. 2021;78(6):699‐708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7980147</ArticleId>
            <ArticleId IdType="pubmed">33739362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sormani MP, Salvetti M, Labauge P, et al. DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France. Ann Clin Transl Neurol. 2021;8(8):1738‐1744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8351392</ArticleId>
            <ArticleId IdType="pubmed">34240579</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
